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Abstract: The significance of the adjacent cartilage in cartilage defect healing is not yet completely understood. 
Furthermore, it is unknown if the adjacent cartilage can somehow be influenced into responding after cartilage damage. 
The present study was undertaken to investigate whether the adjacent cartilage can be better sustained after 
microfracturing in a cartilage defect model in the stifle joint of sheep using a transcutaneous treatment concept 
(Vetdrop
®
). 
Carprofen and chito-oligosaccharids were added either as single components or as a mixture to a vehicle suspension 
consisting of a herbal carrier oil in a water-in-oil phase. This mixture was administered onto the skin with the aid of a 
specific applicator during 6 weeks in 28 sheep, allocated into 6 different groups, that underwent microfracturing surgery 
either on the left or the right medial femoral condyle. Two groups served as control and were either treated intravenously 
or sham treated with oxygen only. Sheep were sacrificed and their medial condyle histologically evaluated qualitatively 
and semi-quantitatively according to 4 different scoring systems (Mankin, ICRS, Little and O’Driscoll). 
The adjacent cartilage of animals of group 4 treated transcutaneously with vehicle, chito-oligosaccharids and carprofen 
had better histological scores compared to all the other groups (Mankin 3.3±0.8, ICRS 15.7±0.7, Little 9.0±1.4). 
Complete defect filling was absent from the transcutaneous treatment groups. 
The experiment suggests that the adjacent cartilage is susceptible to treatment and that the combination of vehicle, chito-
oligosaccharids and carprofen may sustain the adjacent cartilage during the recovery period. 
Keywords: Transcutaneous application system, adjacent cartilage, cartilage defect model. 
INTRODUCTION 
 Current cartilage repair concepts such as autologous 
cartilage implantation (ACI) [1], matrix-associated 
autologous chondrocyte implantation (MACI) [2] and/or 
tissue engineered cartilage [3, 4] defect filling face the 
problem of deficient bonding and integrating of the newly 
formed tissue to the adjacent cartilage. This phenomenon not 
only occurs in defect filling concepts, but is also seen in 
marrow stimulating techniques such as microfracture [5, 6] 
and Pridie drilling [7, 8]. In histological sections, the 
adjacent cartilage is commonly shown to undergo 
degradation indicated by diminished metachromatic staining 
because of proteoglycan loss, clustering of chondrocytes and 
superficial fibrillation [9-11]. Shapiro et al. considered that 
micromotion through mechanical shear stress between the 
new and the host tissue could lead to displacement and 
microfissures and initiate a degenerative process [9]. 
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 The significance of the adjacent cartilage in defect repair 
is not yet fully understood and studies investigating the 
adjacent cartilage are rare [9, 11-13]. It is unknown whether 
the viability of the adjacent cartilage can be sustained after a 
lesion and thus, improves the integration and bonding of new 
tissue. 
 The present animal study focused on the sustainability of 
the adjacent cartilage and whether the properties of the 
adjacent cartilage can be influenced pharmaceutically during 
healing. To do so, a novel transcutaneous treatment concept 
(Vetdrop
®
), was used. The concept is based on liposomal 
vesicles and oxygen delivery of cartilage-modifying 
medications that can be administered transcutaneously onto 
the affected joint area. So far, this application was used for 
the treatment of joint diseases in horses with excellent 
clinical outcomes. Apart from applications used in this study, 
another mixture based on hyaluronic acid (0.5%) is also 
available for horses. Furthermore, liposomal transcutaneous 
therapy has recently gained popularity for human 
applications [14, 15] with good patient compliance resulting 
from easy application, with only minor side effects [16]. 
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 The aim of the present study was to show whether the 
adjacent cartilage in a defect is susceptible to the 
transcutaneously delivered pharmaceuticals and therefore, 
can be manipulated for better defect healing. The study was 
based on the hypothesis that the adjacent cartilage of a 
primary defect could be better preserved through 
transcutaneously administered anti-inflammatory medication 
and thus, result in better bonding to the newly formed tissue. 
It was expected that the transcutaneously treated groups 
show a better histological outcome than the control, 
systemically or sham treated groups. To test the hypothesis, 
we utilized a sheep microfracturing joint defect model. 
MATERIALS & METHODS 
Transcutaneous Treatment Concept 
 The transcutaneous treatment system (Vetdrop
®
) was 
developed by MedDrop Technology AG (Thundorf, 
Switzerland) for transcutaneous application of natural and 
synthetic pharmaceutical ingredients (Fig. 1). The system 
consists of an oxygen generator and an application system, 
which is used in connection with specially developed 
vehicles. The oxygen generator is extracting oxygen from 
the atmosphere and this high concentrated oxygen serves as 
a propellant. The oxygen is first stored in a pressure 
container and during treatment the oxygen flows through a 
pressure reducing valve and a treatment tube to the 
application device. 
 
Fig. (1). Transcutaneous Treatment Concept. Schematic design 
of the transcutaneous application with Vetdrop
®
.
 The applicator serves as a nano-dispersion-device 
consisting of a drug reservoir, which lies within a gas tank. 
The pharmaceutical ingredients are filled into the drug 
reservoir through a port. Oxygen arrives in the gas tank 
through an adapter. The drug reservoir is surrounded by the 
gas tank and ends in a delivery spout that encloses a diffuser. 
The oxygen propels and transports the carrier substance 
under pressure through the diffuser while also mixing with it. 
The assembling of the diffuser utilizes the so-called Venturi-
Effect (fluid pressure decreases in response to a constricted 
area of flow), in order to atomise the micro emulsion. The 
size of the droplets lies in the range of nanometers. The size 
is regulated via a needle lace, which is altering the width of 
the port. 
 The employed micro emulsions are a proprietary product 
of Arvine Pharma AG (MedVital Serum, Arvine Pharma 
AG, Thundorf Switzerland). The vehicles are based on an 
oil-in-water or water-in-oil micro emulsion. The active 
ingredients are incorporated into their watery phase. To 
emulsify, the ingredients are bond in adducts with adjuvants 
and their surface tension is broken. In this way, the 
pharmaceutically active ingredients are dissolved and no 
particle binding occurs, which allows a safe use in the micro- 
and nano sizes. 
Animals 
 Twenty-eight Swiss alpine sheep between 2 and 3 years 
(average 2.5 years) of age and body weights between 48 – 76 
kg (average 59.4 kg) were randomly allocated into 6 groups. 
Four groups with 6 animals each were used for 
transcutaneous treatment and 2 groups with 2 animals each 
were used as controls. 
 Ten days before surgery, the sheep were brought to our 
facilities and adapted to their new environment. Prior to 
surgery, the sheep were fasted for 24 h with water available 
ad libitum. All experiments were conducted according to the 
Swiss regulations of animal welfare and were authorized by 
the local authorities (application No 193/2010). 
Anaesthesia 
 The animals were sedated with xylazine (Xylazine, 
0.1mg/kg BW; Streuli Pharma AG, Uznach, Switzerland) 
and buprenorphine (Temgesic
®
, 0.01mg/kg BW; Essex 
Chemie AG, Luzern, Switzerland) both i.m.. Anaesthesia 
was induced with diazepam (Valium
®
, 0.1mg/kg BW; Roche 
Pharma AG, Reinach, Switzerland), ketamine i.v. (Ketasol
®
, 
2mg/kg BW; Dr. E. Graeub AG, Bern, Switzerland) and 
propofol i.v. (Propofol 1% Fresenius Kabi
®
, 0.4mg/kg BW; 
Fresenius Kabi (Schweiz) AG, Stans, Switzerland. The 
animals’ tracheas were intubated and anaesthesia was 
maintained with 1- 1.5% isoflurane (Isoflo
®
, Abbott AG, 
Baar, Switzerland) and propofol as a constant rate infusion 
(0.01mg/kg BW/min). Furthermore, the animals received an 
infusion of Ringer’s lactate solution at a rate of 10ml/kg 
BW/hr. 
 Equine tetanus serum, s.c. (Tetanus serum 3000 IU, 
Veterinaria AG, Zürich, Switzerland), was given as a single 
dose. For pre- and post-operative antibiotic prophylaxis 
Benzylpenicillin (Procain-Penicillin Streuli
®
 ad us. vet., 
30’000 IU/kg BW, BID; Streuli Pharma AG, Uznach, 
Switzerland) and Gentamicin (Vetagent
®
 ad us. vet., 6mg/kg 
BW, SID; Veterinaria AG, Zürich, Switzerland) were given 
i.v. for 4 days. 
Surgical Procedure 
 Each sheep was placed in dorsal recumbence with the 
limb to be operated upright and fixed in maximal flexion. In 
this position, the weight-bearing condyle of the femur is 
exposed in an optimal way and when the limb is back in 
extension the created defect lies very central to the axis of 
weight bearing forces. 
 The approach to the joint was achieved through a medial 
para-patellar approach extending from the medial patellar 
ligament distally to the tibial tuberosity. The subcutaneous 
tissue and the superficial fascia were cut and the joint was 
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opened just above the weight-bearing part of the medial 
femur condyle. The adipose tissue was partially taken away 
to gain a better insight into the joint. The surgery site was 
kept open with the help of a Weitlaner retractor. A punch-
biopsy trocar ( 6mm) was used to place a round defect into 
the hyaline cartilage in the middle of the condyle. The so-
called “mango-technique” was used to cut the cartilage 
within the circle with a scalpel blade size 11 like a map grid. 
Afterwards, the cartilage pieces were easily removed from 
the subchondral bone without further damaging the cartilage 
wound edges. The calcified cartilage zone was removed with 
a head burr, being careful not to the subchondral bone plate. 
Four (4) small holes were placed with a micro-pic instrument 
and evenly distributed within the defect through the tidemark 
of the subchondral bone as earlier described by Steadman 
and Frisbie [5]. After flushing, the joint was closed with an 
interlocking suture through the fascia and the joint capsule 
(Vicryl 2-0) and a simple continuous suture for the subcutis. 
The cutis was closed with staples. 
 After recovery, the sheep were kept in groups of three or 
four in the stable with free access to food and water. 
Postoperative Management 
 The sheep were treated 3 times per week with the 
transcutaneous treatment system Vetdrop
®
 for 15 minutes 
during 6 weeks. The first treatment took part immediately after 
recovery from surgery and then every 2-3 days for a total of 18 
applications. The area around the stifle was kept free from hair 
and the skin was cleansed with ethanol before administering the 
therapy. The applicator was held at a distance of approximately 
1cm from the treated area in an angle of 90 degrees. The areas 
of skin around the stifle joint were treated with a square area of 
approximately 10 cm
2 
on the medial side of the limb, medial to 
the surgical wound and an equally sized area lateral to the 
surgical wound. The employed ingredients in the mixture varied 
depending on the group allocation. For treatment of groups 1 – 
3, the supplier (MedDrop Technology AG) provided the pre-
assembled formulations. For the treatment of group 4 
(VECHCA), two components were mixed together just before 
application. Component A consisted of vehicle and carprofen 
and component B consisted of vehicle only. The carprofen 
concentration in component A was 13.39%. Components A & 
B were mixed in a 1:1 ratio. Due to possible fluctuations during 
the procedure of mixing a variation of ± 15% was probable, 
such that a carprofen concentration between 5.7% and 7.7% 
(mean 6.7%) was assumed. Group 1 (VE; 6 sheep) was treated 
with vehicle only, group 2 (VECH; 6 sheep) with vehicle and 
chito-oliogosaccharids (2%), group 3 (VECA; 6 sheep) with 
vehicle and carprofen (5.74%), group 4 (VECHCA; 6 sheep) 
with vehicle, chito-oligosaccharids (2%) and carprofen (6.7 ± 
15%), group 5 (S; 2 sheep) served as control and was sham 
treated with oxygen only and group 6 (CA; 2 sheep) was the 2
nd
 
control group, which was intravenously treated with only 
carprofen (5%). This group received once a day 4mg/kg BW 
carprofen (Rimadyl
®
, Pfizer AG, Zürich, Switzerland) during 4 
days intravenously without transcutaneous application. 
 After the 6 week treatment period, the sheep were 
allowed to roam on the pastures for another 6 weeks until 
sacrifice. They were sacrificed at the university-owned 
slaughterhouse in the animal hospital. 
Harvesting and Preparation of the Bone Samples 
 The femur condyles were harvested and examined for 
macroscopically visible changes, such as inflammation and 
degradation of the defect area (Fig. 2). The contralateral side 
served as control. The defect area was photographically 
documented (Digital-Foto Sony DSC–R1, Sony Corporation) 
as well as qualitatively evaluated. Afterwards, lateral and 
dorsal radiographs of the femural condyles were taken 
(49kV, 1 s, 3 mA; Faxitron X-ray systems, Hewlett Packard, 
Mc Minnville Division, Oregon, USA). 
 The defects were excised from the condyles using a 
special band saw (Kolbe Maschinentechnik GmbH, 
Elchingen, Germany) and samples prepared for histology. 
Bone blocks were fixed in 4% buffered formaldehyde for 1 
week. Thereafter, the samples were dehydrated in a series of 
ethanol, defatted in xylene under vacuum, and embedded in 
methylmethacrylate (methacrylacid–methylester; dibuthyl-
phtalate and perkadox in a proportion 89.5:10:0.5). Ground 
sections (30–40 μm) and thin sections (5 μm) were cut in the 
longitudinal axis with a precision saw (Leica1 SP1600) resp. 
microtome (Leica1 RM 2155; Leica Instruments GmbH, 
Nussloch, Germany). Before the ground sections were glued 
to the Acropal slides (Cementit CA 12; Merz Benteli AG, 
Niederwangen, Switzerland), microradiographs were taken 
(55kV and time frame was adapted to individual specimen, 
Faxitron X- Ray System, Hewlett & Packard, Kodak X-
OMAT MA Film, Kodak, France). 
 Ground sections were surface-stained with toluidine blue, 
whereas thin sections were deplastified with methoxyethyl-
acetate (Merck AG, Zug, Switzerland) and then stained with 
either toluidine blue or von Kossa/McNeal staining. 
Histological Evaluation 
 Four different scoring systems were chosen for 
evaluation of the histology sections: Mankin [17], ICRS I 
[18-20], O’Driscoll [21] and a grading system described by 
Yoshimi et al. [22] and modified by Little et al. [23]. 
 The various defect sections were scored in order to assess 
differences between treatment groups. Furthermore, 
comparisons were made between the defect area and the 
adjacent cartilage sections. For scoring the defect part, the 
Mankin, ICRS and the O’Driscoll score systems were used 
while the adjacent cartilage was scored according to the 
Mankin, ICRS and the Little score system. 
 Before scoring, each section was divided into five parts. 
The sections were divided from left to right with the 
orientation scaling-up. The first part was called “before 
defect”. This cartilage part was within the normal cartilage 
without pathological changes and away from the defect and 
served as control. The second part was called “defect margin 
I”. This part started from the area of first pathological 
changes towards the cartilage defect and ended just before 
the defect itself. The third part consisted of the defect itself. 
After this, there was a second “defect margin II”, which 
started just after the defect part and went as far as 
pathological changes in the cartilage were present. The last 
part was called “after defect” consisting of normal cartilage 
again. 
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 The parts before and after defect were not scored as their 
cartilage showed no pathological changes; they served as 
controls, respectively references to assess changes in the 
other defect parts. Scored were the defect part and defect 
margins I and II. 
Statistical Analysis 
 Mean values were calculated and quantitative data 
generated from the histological grading systems were 
analyzed by two factor analysis of variance (ANOVA) to 
assess overall differences. Post hoc tests (Scheffe and 
Bonferroni) were conducted to determine differences 
between individual groups. All statistical tests were 
performed with a commercially available software (PASW 
Stats for MacIntosh, Version 19, IBM Corporation, Armonk, 
USA). 
RESULTS 
Surgical Procedure 
 The surgery was well tolerated and all animals showed 
immediate and good weight bearing postoperatively. Some 
of the sheep developed a slight to moderate subcutaneous 
hematoma on the medial side of the operated limb (8/28 
sheep). The effusion was removed with a syringe once a 
week if the animals were disabled during ambulation. All 
effusions disappeared after 6 weeks. The surgical technique 
was well standardized and also the transcutaneous treatment 
itself was easy to carry out as scheduled. All animals 
tolerated the 18 applications without complications. 
 
 
Qualitative Evaluation of Adjacent Cartilage 
 All typical changes known to appear in the adjacent part 
of osteoarthritic cartilage or surgically treated cartilage 
defects, respectively, were found. This included disruption of 
the tissue, loss of metachromatic staining and increased 
cluster formation of chondrocytes [11]. Furthermore, bone 
remodelling in the subchondral bone was abundant in all 
groups. The calcified cartilage layer was appropriately 
maintained in all groups. Cyst-like lesions were detected 
only in one case each of group 1 (VE) and 5 (S), and in two 
cases of group 3 (VECA). They appeared oblique and lateral 
of the defect part and stretched into the defect margin. In 
group 1 (VE) few but extensive clusters of chondrocytes 
were observed, and similarly in group 2 (VECH) whereas in 
group 4 (VECHCA) mainly cell duplets were recorded. 
 In groups 3 (VECA) and 5 (S), we recorded many single 
chondrocytes in the adjacent cartilage and an intense 
increase of metachromatic staining (Fig. 3). 
 The adjacent cartilage showed signs of degeneration in 
all groups and no statistically significant differences between 
the groups were found in the adjacent cartilage, except for 
when using the Little scoring system. 
 Group 4 (VECHCA) had less surface irregularities 
visible in the adjacent cartilage as compared to the other 
groups when scored according to Little, and was statistically 
significant (p= 0.01) as compared to group 2 (VECH). 
Cluster formation of chondrocytes was higher in group 6 
(CA). Although this was common in all groups, in group 6,  
 
 
 
Fig. (2). Appearance of the defects after slaughtering: Pictures A – F show an example of the appearance of the defects after slaughtering 
of each group. A Group1 (VE), B Group 2 (VECH), C Group 3 (VECA), D Group 4 (VECHCA), E Group 5 (S), F Group 6 (CA). The 
visual appearance was also within the groups very variable and showed no uniform picture.
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we recorded more multiple clusters. Clusters in groups 3 
(VECA) and 4 (VECHCA) consisted predominately of 
duplets and a few triplets. Adjacent Cartilage in 
groups 1 (VE), 2 (VECH) and 5 (S) had more triplets than 
duplets. 
 Groups 1 (VE), 2 (VECH) and 6 (CA) showed a greater 
decrease in toluidine blue staining, however, differences 
were not statistically significant. Nevertheless, group 4 
(VECHCA) showed an obvious trend for improved 
histological scores as compared to all the other groups using 
all three score systems 
 Cell population viability of the adjacent cartilage was 
maintained in all six groups, and the cartilage mineralization 
was regarded as normal within the calcified zone. 
Nevertheless, the tidemark and subchondral bone revealed 
statistically significant differences: groups 4 (VECHCA) and 
6 (CA) showed lower scores than the other groups (p= 
0.0001, p=0.008 respectively). When comparing the overall 
score group 4 (VECHCA) to groups 1 (VE) and 2 (VECH) it 
was statistically significantly lower (p=0.006, p=0.002 
respectively) (Tables 1-4). 
 Comparisons between the Mankin and the ICRS values 
showed a Pearson’s correlation of -0.638 and therefore 
indicated a strong relationship (p>0.001) (Fig. 4). 
Semiquantitative Evaluation of Adjacent Cartilage 
Qualitative Evaluation of the Defect 
 The defects were partly or only marginally filled with a 
mixture of fibro-cartilaginous, fibrous or soft tissue. A 
normal cartilaginous structure within the defect was not 
identifiable in any group, although differences between 
groups were noticed. Group 6 (CA) had the most cartilage-
like defect filling with a mixture of hyaline-like and 
fibrocartilage, whereas in group 5 (S), the defect was mainly 
filled with soft tissue but no fibrocartilage was visible. The 
soft tissue in group 5 (S), however, was bonding to the 
adjacent cartilage and at the basis of the defect next to the 
subchondral bone, some hypercellular nests of chondrocytes 
were visible. In group 4 (VECHCA) a large number of 
chondrocytes were detected at the base of the defect, but 
otherwise the defect was poorly filled and the replacement 
tissue did not reach the normal surface level. 
 The defect in group 3 (VECA) was mainly filled with a 
mixture of fibrous tissue and fibrocartilage, which also did 

Fig. (3). Group 1 (VE) (Pictures A & B) huge cell nests (red arrow) in the adjacent cartilage and a slight loss of matrix staining visible. The 
viability of the matrix is reduced. (tm=tidemark). (A) The defect part mainly consist of fibrous tissue (red arrows) (B) Group 2 (VECH) 
(Pictures C & D): huge cell nests, but the viability of the matrix in the adjacent cartilage is maintained (C). Similar to Group 1 the Defect in 
Group 2 is filled with fibrous tissue. Though it appears not as dense as in Group 1 (D) Group 3 (VECA) (Pictures E & F): The clusters in the 
adjacent cartilage are visible in colums (red arrows) and there are only very few big cell nests (E). The defect part is mainly filled with a 
mixture of fibro- cartilage (red arrow) and fibrous tissue (tm=tidemark, cc=calcified cartilage) (F) Group 4 (VECHCA) (Pictures G & H): 
The adjacent cartilage appears almost normal hyaline like. Cluster appears as douplets (red arrow) huge cell nests are rare (not shown) (G) 
Migration of cells from the subchondral bone into the defect part (sc=subchondral bone, tm=tidemark) (H) Group 5 (S) (Pictures I & J): 
Cyste like lesion stretching into the adjacent cartilage (ground section 30-40 μm, staining with toluidine blue) (I) Hypercellular chondrocytes 
(red arrows) at the defect basis (tm=tidemark) (J) Group 6 (CA) (Pictures K & L): Huge and numerous cell nests in the adjacent cartilage 
(red arrows) (K) hyaline-like appearance in the defect part (red arrows). Chondrocytes grow from the subchondral bone into the defect part 
(green arrow), similar as in Group 4 (cc= calcified cartilage, sb=subchondral bone, tm=tidemark) (L) (If not elsewise indicated: 5 μm 
section, staining with toluidine blue).
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not reach the normal surface level. In group 2 (VECH), the 
defect was filled to approximately 2/3 with a mixture of 
fibrous and soft tissues. Group 1 (VE) showed more fibrous 
tissue than group 2 (VECH) and had some spots with an 
intense metachromatic staining in the defect area (Fig. 3). 
 
Semiquantitative Evaluation 
Defect 
 The defect part in group 6 (CA) demonstrated the best 
results in total score for all three scoring systems used.  
 
Table 1. Mankin Scores of the Margin & Defect Part 
  
Margin Defect 
Mankin 
Structure Cells Toluidine-Blue Staining 
Tidemark  
Integrity 
Total Structure Cells Toluidine-Blue Staining 
Tidemark  
Integrity 
Total 
Group 1 0.42 ±0.7 1.5 ±0.8 0.9 ±0.5 0.7 ±0.5 3.3 ±1.2 6.0 ±0.0 2.0 ±0.9 2.2 ±1.0 1.0 ±0.0 11.2 ±2.0 
Group 2 1.0 ±1.0 2.0 ±0.0 1.0 ±0.5 0.8 ±0.5 4.8 ±2.0 5.2 ±2.0 2.5 ±0.5 2.5 ±0.5 1.0 ±0.0 11.2 ±2.6 
Group 3 1.1 ±0.9 2.0 ±0.0 0.9 ±0.3 0.5 ±0.3 3.5 ±2.5 6.0 ±0.0 2.5 ±0.8 2.3 ±0.8 1.0 ±0.0 11.8 ±1.6 
Group 4 0.2 ±0.3 1.8 ±0.6 0.7 ±0.37 0.8 ±0.7 3.3 ±0.8 6.0 ±0.0 2.3 ±0.8 1.8 ±1.0 1.0 ±0.0 11.2 ±2.0 
Group 5 0.5 ±0.7 2.0 ±0.0 0.5 ±0.7 0.8 ±0.4 4.0 ±0.0 6.0 ±0.0 2.0 ±0.0 2.0 ±0.0 1.0 ±0.0 11.0 ±0.0 
Group 6 0.8 ±0.4 2.0 ±0.0 1.3 ±0.4 0.8 ±0.4 4.5 ±0.7 3.5 ±3.5 2.0 ±0.0 1.0 ±0.0 1.0 ±0.0 7.5 ±3.5 
 
Table 2. ICRS Scores of the Margin & Defect Part 
  
Margin Defect 
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Group 1 2.3 ±0.9 2.8 ±0.4 1.7 ±0.6 3.0 ±0.0 2.2 ±0.6 3.0 ±0.0 14.8 ±0.7 0.0 ±0.0 1.0 ±1.0 0.3 ±0.8 3.0 ±0.0 2.0 ±0.6 3.0 ±0.0 9.3 ±1.8 
Group 2 1.5 ±1.0 2.8 ±0.4 1.8 ±0.4 3.0 ±0.0 2.1 ±0.2 3.0 ±0.0 14.2 ±0.7 0.0 ±0.0 0.2 ±0.4 0.0 ±0.0 2.0 ±1.0 1.8 ±0.4 2.5 ±1.2 6.5 ±1.2 
Group 3 1.1 ±1.1 3.0 ±0.0 1.8 ±0.5 3.0 ±0.0 1.9 ±0.6 3.0 ±0.0 12.5 ±0.8 0.0 ±0.0 1.0 ±0.9 0.0 ±0.0 3.0 ±0.0 1.8 ±0.4 3.0 ±0.0 8.8 ±1.0 
Group 4 2.5 ±0.9 2.9 ±0.2 1.9 ±0.2 3.0 ±0.0 2.2 ±0.4 3.0 ±0.0 15.7 ±0.7 0.0 ±0.0 0.3 ±0.8 0.0 ±0.0 3.0 ±0.0 1.8 ±0.4 3.0 ±0.0 8.2 ±1.0 
Group 5 3.0 ±0.0 2.5 ±0.7 1.5 ±0.7 3.0 ±0.0 2.0 ±0.0 3.0 ±0.0 15 ±1.2 0.0 ±0.0 0.0 ±0.0 0.0 ±0.0 3.0 ±0.0 2.0 ±0.0 3.0 ±0.0 8.0 ±0.0 
Group 6 0.0 ±0.0 3.0 ±0.0 2.0 ±0.0 3.0 ±0.0 2.0 ±0.0 3.0 ±0.0 13 ±1.2 0.0 ±0.0 1.5 ±0.7 0.0 ±0.0 3.0 ±0.0 2.0 ±0.0 3.0 ±0.0 9.5 ±0.7 
 
Table 3. Scores According to Little of the Margin Part 
  
Margin 
Little 
Structure Cellularity 
Cell  
Cloning 
Territorial  
Toluidine Blue 
Interterritorial  
Toluidine Blue 
Tidemark/Calcified  
Cartilage/Subchondral Bone 
Total 
Group 1 1.1 ±0.5 2.3 ±0.8 3.3 ±0.8 1.4 ±0.6 1.3 ±0.4 3.0 ±0.0 12.3 ±1.5 
Group 2 1.7 ±0.3 1.8 0.4 3.4 ±0.4 1.5 ±0.6 1.3 ±0.4 3.0 ±0.0 12.7 ±1.0 
Group 3 1.2 ±0.6 1.4 ±0.6 2.8 ±1 1.4 ±0.2 0.9 ±0.6 3.0 ±0.0 10.8 ±1.8 
Group 4 0.7 ±0.3 1.3 ±0.5 3.0 ±0.9 0.9 ±0.2 1.1 ±0.7 2.0 ±0.0 9.0 ±1.4 
Group 5 1.0 ±0.7 1.8 0.4 3.0 ±0 1.3 ±0.4 1.3 ±0.4 3.0 ±0.0 11.3 ±0.4 
Group 6 1.0 ±0.0 2.3 ±1.1 3.5 ±0.0 2.0 ±0.0 1.3 ±0.4 2.0 ±0.0 12.0 ±0.7 
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Whereas the differences between the groups after Mankin 
Score were not statistically significant, the O’Driscoll score 
showed a statistically clear trend (group 6 (CA) > Group 1 
(VE) > group 3 (VECA) > group 2 (VECH) > group 5 (S) > 
group 4 (VECHCA)). Furthermore, group 6 (CA) had a 
significantly better overall score than group 4 (VECHCA; 
p=0.017). In the category “hypocellularity”, group 6 (CA) 
had a significantly better score than group 2 (VECH; 
p=0.017) and in “structural integrity” group 6 (CA) was 
significantly better than group 3 (VECA) and group 4 
(VECHCA; p=0.042, p=0.021 respectively). “Surface 
regularity” showed the most statistically significant 
differences: group 2 (VECH) > group 5 (S) (p=0.0019) and 
group 4 (VECHCA; p=0.004), group 3 (VECA) > group 4 
(VECHCA; p=0.0001), group 5 (S) > group 3 (VECA; 
p=0.002), group 6 (CA) > groups 4 (VECHCA) and 5 (S; 
p=0.019, p=0024, respectively). The most favourable ICRS 
Score was demonstrated for group 6 (CA), although it was 
not statistically significant.. The following statistically 
significant differences were recorded for the ICRS score: In 
the category “cell population viability” group 2 (VECH) 
showed inferior scores to groups 1 (VE), 3 (VECA) and 4 
(VECHCA) (all p=0.002). Group 2 (VECH) was overall 
significantly inferior to groups 1 (VE; p=0.002) and 3 
(VECA; p=0.024). Whereas the overall total Mankin score 
showed no differences between the transcutaneously treated 
groups, we found a clearly better trend for group 6 (CA) 
(Tables 1-4). 
 Comparison between the Mankin and ICRS scores 
indicated a Pearson’s correlation of -0.370, which came 
close to attaining statistical significance (p=0.053) (Fig. 4). 
DISCUSSION 
 In the present study, we tested the hypothesis that 
adjacent cartilage and/or a cartilage defect can be influenced 
positively for healing by transcutaneous treatment with 
cartilage preserving ingredients. To do so, four different 
scoring systems were used and it was demonstrated that the 
adjacent cartilage in the transcutaneously-treated group with 
VECHCA (group 4) obtained better histological scores than 
all the other groups. Although not statistically significant, 
except for the Little score, a clear trend was observed for 
different variables. In particular, the metachromatic staining 
was better maintained in group 4 (VECHCA). This indicated 
that the extracellular matrix in this group was better 
preserved compared to the other treatment groups. 
Furthermore, the chondrocyte clusters found were small and 
consisted mostly of duplets or triplets. Clusters are generally 
regarded as being a sign of cartilage degeneration, but can 
also represent an indicator of attempted cartilage repair 
Table 4. O’Driscoll Score of the Defect Part 
  
Defect 
O‘Driscoll 
Cellular  
Morphology 
Staining  
of the  
Matrix 
Surface  
Regularity 
Structural  
Integrity 
Thickness 
Bonding to  
Adjacent Cartilage 
Hypocellularity 
Chondrocyt  
Clustering 
Freedom from  
Degenerative Changes in  
Adjacent Cartilage 
Total 
Group 1 1.0 ±1.0 1.5 ±0.8 1.2 ±1.0 0.5 ±0.5 0.5 ±0.8 1.2 ±0.7 1.3 ±1.0 1.0 ±0.0 2.0 ±0.0 10.2 ±5.0 
Group 2 0.3 ±0.8  1.3 ±0.5 1.7 ±0.8 0.5 ±0.5 0.0 ±0.0 0.5 ±0.5 0.7 ±0.8 1.0 ±0.0 2.0 ±0.0 8.0 ±1.5 
Group 3 0.3 ±0.8 1.3 ±0.5 2.0 ±0.0 0.7 ±0.5 0.2 ±0.4 0.6 ±0.5 1.2 ±1.3 1.0 ±0.0 2.0 ±0.0 8.5 ±3.8 
Group 4 0.3 ±0.8 1.3 ±0.8 0.3 ±0.8 0.0 ±0.0 0.2 ±0.4 0.8 ±0.4 1.2 ±1.0 0.8 ±0.4 1.8 ±0.4 6.8 ±3.7 
Group 5 1.0 ±1.4 1.0 ±0.0 0.0 ±0.0 0.0 ±0.0 0.0 ±0.0 1.0 ±0.0 1.5 ±0.7 1.0 ±0.0 1.5 ±0.7 7.0 ±1.4 
Group 6 2.0 ±0.0 2.5 ±0.9 2.0 ±0.0 1.0 ±0.0 0.5 ±0.7 1.0 ±0.0 3.0 ±0.0 1.0 ±0.0 2.0 ±0.0 15.0 ±1.4 
 
Fig. (4). ICRS versus Mankin histology scores. Comparison between the Mankin and the ICRS score showed meaningful relationship.
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through chondrocyte proliferation [12, 24]. Therefore, only 
big cell nests and a decrease in metachromatic staining were 
considered as negative indicators. 
 The ingredients used in the transcutaneous treatment 
group 4 (VECHCA) were vehicle, chito-oligosaccharids and 
carprofen. Chito-oligosaccharids are derivates of chitosan, 
which has recently gained popularity with cartilage research 
as it proved to be suitable for improving cartilage repair as 
scaffold material [25-33]. Chitosan consists of glucosamine 
and N-acetylglucosamine monomers and has many 
interesting properties in a wide range of biomedical 
applications. Besides its biocompatible and biodegradable 
properties it has a good affinity for proteins, displays 
haemostatic characteristics due to its ability to aggregate 
erythrocytes and activate platelets [34, 35], enhances 
bacterial resistance and also improves wound-healing 
activities. Ueno et al. [36] observed that chitosan derivatives 
have a stimulatory effect on macrophages and are also 
chemoattractants for neutrophils. Furthermore, they 
stimulate granulation tissue formation due to growth factor 
accumulation. Fukui et al. [37] raised the hypothesis that 
skin and cartilage have many features in common and they 
proposed to consider elements of techniques used in wound 
healing, as also being present in cartilage repair. The use of 
chitosan in cartilage repair certainly supports this idea. The 
only constraint in biomedical application of chitosan is that it 
is insoluble under physiological pH conditions. Hydrolyzed 
products such as chito-oligosaccharids, have a lower 
viscosity and have a better solubility at neutral pH due to 
their shorter chain lengths and free amino groups in D-
glucosamine units [38]. This made chito-oligosaccharids 
interesting for many researchers. 
 Our results suggest that the chito-oligosaccharids 
included in our treatment mixture helped to sustain the 
adjacent cartilage. As the same good histological results 
were missing in animals treated with vehicle and chito-
oligosaccharids only, we assume that the combination of 
vehicle and chito-oligosaccharids with carprofen led to this 
better outcome. Carprofen is a widely used non- steroidal 
anti-inflammatory drug (NSAID) in veterinary medicine and 
has strong analgesic, antipyretic and antiphlogistic effects 
[39-41]. Apart from inhibiting the enzyme cyclooxygenase 
(COX), Benton et al. [42] discovered that carprofen also 
stimulated the rate of glucosaminoglycan production in dogs 
and therefore had a positive influence on the synthesis of the 
chondral extracellular matrix. Nevertheless, a concentration 
higher than 20μg/ml had a negative effect on the 
glycosaminoglycan synthesis. We hypothesize that this could 
be the reason why animals treated intravenously with only 
carprofen, had the worst histological scoring outcome in the 
adjacent cartilage. The high amount of carprofen achieved in 
the joint in our study may have inhibited the glucosamino-
glycan synthesis. Although the synovial carprofen 
concentration measured (Fouché et al., 2012) was much 
lower than 20 μg/ml, the histological scores were not as good 
as in group 4 (VECHCA). This may indicate that the 
combination of chito-oligosaccharids and carprofen give rise 
to the better histological outcome since the two ingredients 
seem to have a positive impact on each other. However, the 
meaning of concentrations and combination of ingredients 
needs to be further explored. 
 An observation period of 12 weeks was chosen in the 
current study. We therefore neither expected a complete 
healing of the defect site nor did we intend it. The surgical 
experimental design aimed only to provide and set up the 
cartilage defect with the best possible intrinsic healing 
properties. The focus was set on the early alterations of the 
adjacent cartilage after different transcutaneous 
pharmaceutical treatment. However, the defect itself was 
also examined in order to obtain a more complete impression 
of the individual groups and to detect potential relationships 
between adjacent cartilage and the defect part. Therefore, 
every section was divided into 5 parts and scored separately 
with 4 different histological scores to get as much 
information as possible about the individual sections. 
 Today, many different scoring systems in cartilage repair 
exist. Some were validated and others were aligned. But 
there is still no general consensus about which scores should 
be applied in a specific experimental or clinical setup [43]. 
This means that so far there is no existing valid grading 
system acknowledged as the gold standard [44]. The Mankin 
score is often used to score osteoarthritic cartilage in human 
beings. The score was developed to investigate advanced 
osteoarthritis and is therefore only restrictively applicable for 
mild and early phases of osteoarthritis [45]. Furthermore, 
whereas Van der Sluijs et al. [46] validated the reliability of 
the Mankin score as good, Custers et al. [45] declared that 
the inter- and intraobserver variability of this system is rather 
high. Nevertheless, Ostergaard et al. [44] stated that 
although the Mankin score has some weaknesses, it is still 
valuable for systematic assessment of articular hyaline 
cartilage. Additionally, the Mankin score was applied to 
histological evaluations for many years due to missing 
alternatives, and therefore its outcome is well known [45]. 
Based on these criteria, we included the Mankin score in our 
evaluations. 
 The ICRS score was additionally chosen because it 
incorporates additional features. Whereas the Mankin score 
has only one category for cell scoring, the ICRS includes one 
about cell distribution and another about cell viability. 
Furthermore, the ICRS score also provides special categories 
for the subchondral bone and the calcified cartilage. 
However, the ICRS score does not allow for evaluation of 
staining alterations (metachromasia) or detailed comparison 
of the structure as does the Mankin score. Therefore, 
combining both scoring systems provided more detailed 
information. Besides, Moussavi-Harami et al. [47] compared 
the ICRS to the Mankin score and demonstrated a uniform 
relationship. Comparisons of the Mankin and ICRS scores in 
the margin parts I and II in the current study demonstrated a 
good relationship whereas the comparisons of the respective 
two scores in the defect part did not. This could be due to the 
fact that both, Mankin and ICRS scores were developed to 
score osteoarthritic cartilage and not to score repaired 
cartilage after experimentally created articular defects. While 
the margin part is reflecting more an osteoarthritic cartilage 
the defect part clearly does not. 
 The Little score was selected because it includes all 
features of the Mankin and the ICRS score in one scoring 
system. 
 Finally, the O’ Driscoll score [21] was the first score dev-
eloped specially for cartilage repair and it is recommended 
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for assessing an in vivo repaired cartilage defect [48]. This 
score is very specific for cartilage repair and includes the 
integration of the repair tissue into the adjacent cartilage. 
Therefore, the O’Driscoll score could only be applied within 
the defect part itself. 
 When examining our results, it becomes apparent that 
none of the scoring systems led to the same grading 
sequence of the individual groups. Interestingly, there was a 
clear trend in all score systems for best results in group 4 
(VECHCA) for adjacent cartilage and for group 6 (CA) for 
the defect part. As this trend was observed in every scoring 
system it seems reasonable to rely on it. However, when 
looking at the other groups,, the overall picture was not as 
clear as expected, since between groups 1 (VE), 2 (VECH), 
3 (VECA) and 5 (S) the different scoring systems revealed 
dissimilar results. Therefore, an explicit conclusion may be 
only found for groups 4 (VECHCA) and 6 (CA) and leaving 
the results for the other groups ambiguous. The reasons for 
these different outcomes in the various scorings are probably 
multifaceted: long lasting experience and both, the reliability 
and the validity of the semi-qualitative scores may be 
diversely assessed by investigators and be subjective [20, 44, 
46-51]. In addition, focus was placed specifically on the 
adjacent cartilage. So far, this has not been very common 
and thus more general histological grading scores are 
developed to score either osteoarthritic, tissue engineered or 
repaired cartilage defect. They may not be simply 
transferable to our specific case. Nevertheless, we chose 
common histological grading systems because we assumed 
more objective and acceptable results than with an own, 
newly created scoring scale. On the other hand, sections 
were divided into different parts to maximise 
standardization. Nevertheless, it could be shown with all 4 
score systems that with the transcutaneous application of 
cartilage protecting medication, the adjacent cartilage of a 
defect could be better preserved. 
 The significance of this study for clinical applications is 
such that the transcutaneous treatment system could be an 
alternative or additional treatment option for patients 
suffering from a cartilage defect. As the transcutaneously 
applied ingredients seem to sustain the viability of the 
adjacent cartilage, the immediate environment of the graft-
host interface and the integration of bone marrow derived 
repair tissue, namely the native cartilage, could be improved. 
In addition, the transcutaneous treatment system is in 
accordnace with high patient compliance since the treatment 
is free of pain. 
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